Immunoglobulin News and Research

RSS

Hay fever symptom severity plateau identified

Study findings suggest that individuals sensitized to Poaceae, a family of land grasses, experience increasing severity in hay fever symptoms in line with daily levels, up to a saturation point.

2 Jul 2012

Link between phthalates and early eczema uncovered

Research published in Environmental Health Perspectives suggests that prenatal exposure to butylbenzyl phthalate, a common component of vinyl flooring, may increase a child’s risk for developing early eczema.

29 Jun 2012

FDA approves test for dengue virus infection

The first test that can detect the presence of the dengue virus itself rather than antibodies to the virus has been approved for use by the US Food and Drug Administration.

27 Jun 2012

China SFDA approves China Biologic's Human Coagulation Factor VIII

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").

25 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

Skin infections in AD patients linked to PMN impairment

Impairment of polymorphonuclear granulocytes among patients with atopic dermatitis may represent an additional cause of skin infections, suggest study findings.

22 Jun 2012

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today that AP-HP (Assistance Public - Hôpitaux de Paris) sponsor of the ARACHILD study presented at the EAACI Congress a late breaking oral presentation on safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut.

18 Jun 2012

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Pharmacyclics, Inc announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

18 Jun 2012

Researchers identify prognostic marker in chronic lymphocytic leukemia

Researchers have identified a prognostic marker in the most common form of chronic leukemia that can help to distinguish which patients should start treatment quickly from those who can safely delay treatment, perhaps for years.

13 Jun 2012

Failing combination asthma therapy may lead to SAFS in children

New research presented at the ATS 2012 International Conference in San Francisco suggests that a significant proportion of children with asthma failing Step 4 or greater therapy may have severe asthma with fungal sensitization (SAFS).

23 May 2012

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.

7 May 2012

CSL Behring commences C1-INH phase I/II study in hereditary angioedema

CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema.

4 May 2012

New test accurately detects aggressive prostate cancer

One in six men will be diagnosed with prostate cancer during his lifetime, the second leading cause of death among men in the United States. It's a serious problem and current diagnostic tests aren't very specific. But a research team at the University of Central Florida NanoScience Technology Center has found a more accurate test that not only determines whether a patient has prostate cancer, but also how aggressive it is.

26 Apr 2012

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology.

27 Mar 2012

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

26 Mar 2012

New IVIG trial can reduce OCD symptoms in children with PANDAS

Criteria for a broadened syndrome of acute onset obsessive compulsive disorder (OCD) have been proposed by a National Institutes of Health scientist and her colleagues. The syndrome, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), includes children and teens that suddenly develop on-again/off-again OCD symptoms or abnormal eating behaviors, along with other psychiatric symptoms - without any known cause.

26 Mar 2012